Assiut University
Asyut, Egypt
NCT Number: NCT07204769
Aims of the Research:
1. Isolation and identification of Providencia spp. from UTIs. 2. Genotypic confirmation of Providencia isolates. 3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp. 4. Characterization of some virulence factors of Providencia spp. 5. Molecular characterization of multidrug-resistance gene antibiotics. 6. Determination of risk factors for Providencia UTIs.
Trial opening soon.
Get NotifiedAll sexes
Observational
Asyut, Egypt
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, with Escherichia coli, Klebsiella spp., Proteus spp., and Pseudomonas spp. representing the majority of isolated pathogens in both community and hospital settings. Providencia spp., although historically considered uncommon, are increasingly recognized as opportunistic pathogens.
International surveillance studies report that Providencia accounts for ~1-2% of urinary isolates, with higher prevalence (up to 6-12%) in catheter-associated infection.
The Providencia genus, nestled within the Enterobacterales order as part of Proteus and Morganella relatives, consists of Gram-negative bacteria that are adept at producing urease .
The genus includes 14 distinct species, with Providencia rettgeri, Providencia stuartii, Providencia alcalifaciens, and Providencia hangzhouensis standing out due to their pronounced relevance to human infections. Renowned for their association with urinary tract infections, these pathogens also possess the capability to inflict a broader spectrum of severe ailments, such as ocular diseases,peritonitis, neonatal septicemia or bloodstream infections and meningitis.
Providencia stuartii is able to adhere to and invade HeLa-M epithelial cell line.
They form biofilms and have several virulence genes . Providencia spp. may be susceptible to third- and fourth-generation cephalosporins, aztreonam, imipenem, and meropenem. Providencia species have variable susceptibilities to fluoroquinolones, aminoglycosides, and trimethoprim- sulfamethoxazole (TMP-SMX). Generally, Providencia spp. are frequently resistant to tetracyclines, penicillins, and first- and second- generation cephalosporins .
Providencia spp.are intrinsically resistant to polymyxins and tigecycline, which are considered last- resort antibiotics for other resistant pathogens .
In Egypt, several studies have investigated the prevalence of UTI pathogens, consistently reporting E. coli, Klebsiella spp., and Proteus spp. as the most frequent isolates .
However, no published Egyptian data specifically describe the prevalence, antimicrobial resistance patterns, or clinical significance of Providencia spp. in UTIs.
This gap highlights the need for focused research on Providencia in the Egyptian context. Studying its frequency, antibiotic resistance mechanisms, and clinical relevance would not only provide novel insights but also contribute to improving diagnosis, empirical therapy, and infection control strategies in Egyptian hospitals .
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with UTI diagnosed through clinical examination and urine analysis. Informed consent will be obtained from each patient before Participation in the study.
Exclusion criteria
Molecular characterization of multidrug-resistance gene antibiotics.
Time frame: Through study completion, an average of 1 year
Contact information is provided by the study sponsor or research team.
Aya Tareq Diab, Bachelor's degree
CONTACT
Rawhia Fathy Abdel-Hamid, Doctorate
CONTACT
Assiut University
Other
Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06822751
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystitis
Elbeuf, France
View Trial DetailsNCT07532941
Cellulitis, Connective Tissue Diseases
Melbourne, Victoria, Australia
View Trial DetailsNCT07411209
Asymptomatic Bacteriuria, Female Urogenital Diseases
Madison, Wisconsin, United States
View Trial DetailsNCT07508124
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial Details